Insider Trading Alert - UNP, QCOR And ZION Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 13, 2014, 117 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,198.88 to $4,397,881,850,959.55.

Highlighted Stocks Traded by Insiders:

Union Pacific (UNP) - FREE Research Report

Totusek Jeffrey P who is Vp Controller & Cao Upc at Union Pacific sold 1,166 shares at $179.25 on Feb. 13, 2014. Following this transaction, the Vp Controller & Cao Upc owned 63,666 shares meaning that the stake was reduced by 1.8% with the 1,166-share transaction.

The shares most recently traded at $179.38, up $0.13, or 0.07% since the insider transaction. Historical insider transactions for Union Pacific go as follows:

  • 4-Week # shares sold: 1,028
  • 12-Week # shares sold: 16,414
  • 24-Week # shares sold: 26,414

The average volume for Union Pacific has been 2.0 million shares per day over the past 30 days. Union Pacific has a market cap of $81.4 billion and is part of the services sector and transportation industry. Shares are up 6.33% year-to-date as of the close of trading on Thursday.

Union Pacific Corporation, through its subsidiary, Union Pacific Railroad Company, provides rail transportation services in North America. The stock currently has a dividend yield of 2.04%. The company has a P/E ratio of 19.0. Currently there are 14 analysts that rate Union Pacific a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UNP - FREE

TheStreet Quant Ratings rates Union Pacific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Union Pacific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Questcor Pharmaceuticals (QCOR) - FREE Research Report

Broadwood Partners Lp who is Director at Questcor Pharmaceuticals sold 85,000 shares at $69.10 on Feb. 13, 2014. Following this transaction, the Director owned 5.3 million shares meaning that the stake was reduced by 1.58% with the 85,000-share transaction.

The shares most recently traded at $69.93, up $0.83, or 1.18% since the insider transaction. Historical insider transactions for Questcor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 70,000
  • 12-Week # shares sold: 70,000
  • 24-Week # shares bought: 3,250
  • 24-Week # shares sold: 570,000

The average volume for Questcor Pharmaceuticals has been 2.0 million shares per day over the past 30 days. Questcor Pharmaceuticals has a market cap of $4.2 billion and is part of the health care sector and drugs industry. Shares are up 27.81% year-to-date as of the close of trading on Thursday.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. The stock currently has a dividend yield of 1.73%. The company has a P/E ratio of 16.0. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on QCOR - FREE

TheStreet Quant Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Questcor Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Zions (ZION) - FREE Research Report

Atkin Jerry C who is Director at Zions bought 24,000 shares at $25.00 on Feb. 13, 2014. Following this transaction, the Director owned 24,000 shares meaning that the stake was reduced by 100% with the 24,000-share transaction.

Cash R D who is Director at Zions bought 4,000 shares at $25.15 on Feb. 13, 2014. Following this transaction, the Director owned 2,000 shares meaning that the stake was reduced by 200% with the 4,000-share transaction.

The shares most recently traded at $30.92, up $5.77, or 18.66% since the insider transaction. Historical insider transactions for Zions go as follows:

  • 4-Week # shares sold: 23,985
  • 12-Week # shares sold: 28,209
  • 24-Week # shares sold: 35,781

The average volume for Zions has been 2.0 million shares per day over the past 30 days. Zions has a market cap of $5.5 billion and is part of the financial sector and banking industry. Shares are down 3.44% year-to-date as of the close of trading on Thursday.

Zions Bancorporation, a financial holding company, provides banking and related services in the United States. The stock currently has a dividend yield of 0.55%. The company has a P/E ratio of 18.3. Currently there are 3 analysts that rate Zions a buy, 1 analyst rates it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ZION - FREE

TheStreet Quant Ratings rates Zions as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full Zions Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Rises for First Time in 9 Days, Oil Jumps as OPEC Agrees to Boost Output

Dow Rises for First Time in 9 Days, Oil Jumps as OPEC Agrees to Boost Output

German Automakers Slump After Trump Tweets New Tariff Threat

German Automakers Slump After Trump Tweets New Tariff Threat

Chipotle Rises After Wedbush Lifts Price Target

Chipotle Rises After Wedbush Lifts Price Target

Crude Rises on OPEC Deal That Doesn't Specify Output Boost

Crude Rises on OPEC Deal That Doesn't Specify Output Boost

Video: Stock Investors Shouldn't Fret About Oil Prices in the $60s

Video: Stock Investors Shouldn't Fret About Oil Prices in the $60s